CliffBio
small molecule

ORPHENADRINE CITRATE

ORPHENADRINE CITRATE

Loss of exclusivity—loss of exclusivity
CompanyJEROME STEVENS PHARMACEUTICALS INC

Drug detail

Brand nameORPHENADRINE CITRATE
Active ingredientORPHENADRINE CITRATE
Strength100MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2000
Marketing statusDISCN

More from JEROME STEVENS PHARMACEUTICALS INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ORPHENADRINE CITRATE patent cliff — loss of exclusivity — | CliffBio